By Danny Sullivan – Longevity.Technology –
Biopharma giant commits $100m annually to Regeneron Ventures as it seeks to ‘fuel promising biotech innovation.’
Yesterday, as we revealed 2023 was another tough year for longevity investment, biotech heavyweight Regeneron quietly announced the formation of Regeneron Ventures, a new $500 million venture capital fund. As the fund’s exclusive limited partner, Regeneron has pledged $100 million annually over the next five years to invest in promising life sciences companies.
